DURHAM, N.C., July 2, 2018 — Premier Research’s head of patient engagement will talk about the role of natural history studies in clinical research at the International Children’s Advisory Network’s Research & Advocacy Summit on July 12 in Edinburgh, U.K.
Juliet Moritz, the CRO’s Executive Director, Program Strategy, Rare Disease and Pediatrics/Patient Engagement, will discuss the importance of natural history studies in researching pediatric drugs at iCAN’s fourth annual Advocacy Summit, July 9-13. Her 30-minute presentation will begin at 12:30 p.m.
Ms. Moritz will describe what natural history studies are, explain their importance, and address how researchers performing these studies can best interact with children.
iCAN advocates for children involved in clinical drug research, working to improve pediatric healthcare by giving children and their families a more prominent voice in health, research, medicine, and innovation.
About Premier Research
Premier Research is a leading clinical development service provider that helps biotech and specialty pharma innovators — small companies with big ambitions — transform life-changing ideas into new medicines. The company applies a relentless focus on quality in the execution of global, regional, and local clinical development programs with a special focus on addressing unmet needs in areas such as analgesia, dermatology, medical devices, neuroscience, oncology, pediatrics, and rare disease. Premier Research operates in 84 countries and employs 1,250 professionals, including a strong international network of clinical monitors and project managers, regulatory, data management, statistical, scientific, and medical experts. They are focused on smart study design for advanced medicines that transform breakthrough biotech thinking into reality.